Benjamin Shaker - 15 Mar 2023 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Markets Officer
Signature
/s/ Steve Meetre, as Attorney-in-Fact
Issuer symbol
AGL
Transactions as of
15 Mar 2023
Net transactions value
-$1,948,204
Form type
4
Filing time
17 Mar 2023, 16:55:46 UTC
Previous filing
16 Feb 2023
Next filing
18 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $70,000 +70,000 +273% $1.00* 95,625 15 Mar 2023 Direct F1
transaction AGL Common Stock Options Exercise $25,000 +25,000 +26% $1.00* 120,625 15 Mar 2023 Direct F1
transaction AGL Common Stock Sale $833,231 -35,000 -29% $23.81 85,625 15 Mar 2023 Direct F1, F2
transaction AGL Common Stock Sale $595,075 -25,000 -29% $23.80 60,625 15 Mar 2023 Direct F1, F3, F4
transaction AGL Common Stock Options Exercise $25,000 +25,000 +41% $1.00* 85,625 16 Mar 2023 Direct F1
transaction AGL Common Stock Sale $111,741 -4,588 -5.4% $24.36 81,037 16 Mar 2023 Direct F1, F3, F5
transaction AGL Common Stock Sale $252,192 -9,831 -12% $25.65 71,206 16 Mar 2023 Direct F1, F3, F6
transaction AGL Common Stock Sale $275,965 -10,581 -15% $26.08 60,625 16 Mar 2023 Direct F1, F3, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Right to buy) Options Exercise $0 -70,000 -21% $0.000000 257,306 15 Mar 2023 Common Stock 70,000 $1.00 Direct F8
transaction AGL Options (Right to buy) Options Exercise $0 -25,000 -48% $0.000000 26,851 15 Mar 2023 Common Stock 25,000 $1.00 Direct F9
transaction AGL Options (Right to buy) Options Exercise $0 -25,000 -93% $0.000000 1,851 16 Mar 2023 Common Stock 25,000 $1.00 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.50 to $24.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.52 to $24.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.98 to $24.975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.98 to $25.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $25.98 to $26.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F8 These options were granted on December 30, 2016, and became fully vested as of January 12, 2021.
F9 These options were granted on April 27, 2017, and became fully vested as of January 12, 2021.

Remarks:

Exhibit List: Ex.24 - Power of Attorney